Earnings call transcript: Investor AB posts 9% NAV growth in Q2 2026

Investor AB reported Q2 2026 adjusted net asset value of SEK 1,215bn, up 9% from Q1, and a 15% total shareholder return on its B share, but the shares were flat at $35.6. The increase was driven by listed holdings (+14% total return), which outweighed valuation compression at Patricia Industries (-3%) and weaker EQT investments (-2%), with Patricia subsidiaries still growing organically (7% sales, +16% adjusted EBITDA). Management highlighted AI as a long-term innovation driver for portfolio companies while flagging risks from valuation pressure and softer wound-care demand in mature markets.

Analysis

The signal here is less about a one-quarter NAV bump and more about portfolio convexity: listed industrials tied to electrification/data-center capex are now doing the heavy lifting, while the private-asset/medtech sleeve is behaving like a duration trade that still has not fully adjusted to lower multiples. That makes the holding company look like a quiet beneficiary of the AI buildout through suppliers to the physical layer, not just a passive financial conglomerate. The second-order point is that this mix should keep Investor AB relatively resilient if capex stays strong, but it also caps enthusiasm because the market is not yet paying for the underlying EBITDA growth in the private assets.

The main risk over the next 1-3 months is that the market continues to treat the medtech drag as structural rather than cyclical, which would keep the stock range-bound even if operating performance improves. Over 6-18 months, the key catalyst is whether lower rates and stable comps let Patricia re-rate back toward its intrinsic growth profile; if not, the NAV uplift from listed holdings will leak away into discount/premium noise. Falsifiers are clear: persistent sub-market wound-care growth, further multiple compression in European medtech, or any slowdown in the AI/infrastructure capex cycle that would hit the listed winners first.

Contrarian take: consensus may be underappreciating how much of the good news is already in the listed-book winners and overestimating the permanence of the Patricia discount. If medtech pricing stabilizes, the current setup becomes a visible earnings-to-NAV catch-up story rather than a value trap. The cleaner expression of the AI theme remains direct infrastructure beneficiaries rather than the holding company wrapper.

Key Decisions for Investors

• Hold IVSBF, but do not chase it here; add only on a 3-5% pullback or if the next print shows Patricia multiples stabilizing. Time horizon: 1-3 months. Risk/reward: limited upside near the top of the range unless the medtech discount narrows.
• Long TSM on any AI-capex weakness over the next 2-6 weeks. It is a cleaner expression of the infrastructure spend that is implicitly helping Investor’s listed-book winners. Falsifier: signs of order normalization or guidance cuts in the AI supply chain.
• Use NDAQ as a higher-quality AI monetization proxy over 6-12 months if you want software/data exposure without the physical-capex risk. The article’s key lesson is that deep customer integration and data flows are where AI gets monetized first. Falsifier: spending hesitation from enterprise clients or slower productization of AI features.
• Set an alert on IVSBF for any 5%+ widening in the holding-company discount versus NAV. If that occurs while operating performance remains intact, it becomes a more attractive entry than buying strength.